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ABSTRACT
Objective: Antioxidant probably can prevent the progression and complications of Type 2 diabetes mellitus (T2DM). Due to effectiveness of alpha 
lipoic acid (ALA) as an antioxidant, this study was done in T2DM patients to evaluate the effect of ALA on their diabetic status, lipid profile, and 
oxidative stress (OS) status.
Methods: A total of 35 patients with diabetes were selected randomly who were under insulin treatment mainly and grouped as Group “A.” Another 
age- and sex-matched healthy controls selected grouped as “B.” Both groups supplemented with ALA (300 mg/day) for 6 months continuously. All 
parameters were tested before and after the supplementation.
Results: There was a significant decrease in fasting blood sugar from 161 to 122 mg/dl in Group “A” and from 98 to 90 mg/dl in Group “B.” Postprandial 
blood sugar (PPBS) and glycosylated hemoglobin (HbA1c) levels also significantly decreased from 211 to 158 mg/dl and 8.81% to 7.2%, respectively, 
in Group “A.” PPBS levels significantly decreased from 130 to 124 mg/dl in Group “B,” but HbA1c% decreased insignificantly from 5.26% to 5.24% 
in Group “B.” Lipid profile parameters decreased in both groups except triglyceride level, which show insignificant relation in Group “B.” OS marker 
malondialdehyde significantly decreased from 1.967 to 1.592 nm/ml in Group “A” and from 0.613 to 0.472 nm/ml in Group “B.” Plasma antioxidant 
glutathione shows a significant increase in both groups from 2.117 to 2.405 µmol/L in Group “A” and from 2.631 to 2.811 µmol/L in Group “B.” Plasma 
nitric oxide also shows significant increase in both groups from 1.712 to 1.990 µmol/L and from 2.139 to 2.318 µmol/L, respectively.
Conclusion: Therefore, ALA is a potent antioxidant and can be used against oxidative injury associate with T2DM.
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INTRODUCTION
As a chronic metabolic disorder, diabetes mellitus (DM) characterized 
by hyperglycemia due to defect in secretion or action of insulin or 
both, this causes imbalance in carbohydrate and fat metabolism [1]. 
DM is mainly categorized into Type 1 and Type 2. Type 1 DM (T1DM) 
is primarily due to autoimmune pancreatic ß-cell destruction. Type 2 
DM (T2DM) is the frequent form and is due to impaired insulin 
secretion or insulin resistance [2]. According to the Diabetes Atlas 
2011, the incidence of diabetes is increasing and expected to reach 
from 366 million in 2011 to 552 million by 2030 [3]. Due to diversity 
of manifestation of disease and its complications, it causes a great 
human suffering physically, mentally, and even economically, even 
with the enormous available facilities to control the disorder [4]. In 
the disease progression, the prolonged exposure to hyperglycemia 
causes many long-term microvascular or macrovascular complications 
involving cardiovascular system, excretory system, nervous system 
causes diabetic cardiomyopathy, diabetic retinopathy, and neuropathy, 
which are prime cause of disability, morbidity, and premature death in 
T2DM [5,6].
Oxidative stress (OS) results insulin resistance in T2DM [7]. 
Hence, number of studies done to know the effect of antioxidant 
supplementation in T2DM treatment, where some found positive 
result [8-10], while others found none [11]. Alpha lipoic acid (ALA) a 
both fat and water soluble antioxidant may help in regenerating other 
antioxidants and make them active again so often termed as “universal 
antioxidant.” ALA might protect metabolic syndromes such as DM, 
improving insulin sensitivity and preventing distal sensory-motor 
diabetic neuropathy [12]. According to Blumenthal study, ALA in their 
experimental study improved the glycemic condition by acting on the 
liver [13].
However, there are some inconclusive evidences regarding its action in 
defending the OS level, improving the conditions of insulin deficiency 
and improvement of lipid profile level in T2DM patients. They are 
mostly done on animals [14,15]. As the T2DM incidence is increasing 
rapidly, the present study was undertaken to explore the effect of ALA 
supplementation on glycemic indexes, lipid profiles, and OS markers in 
T2DM patients.
METHODS
This was a prospective study including patients who were attending 
Endocrinology Department (both indoor and outdoor) and their 
biomolecular investigations were carried in Physiology Department 
and Biochemistry Department, IMS and SUM Hospital, Bhubaneswar. 
The institutional ethical committee approval was obtained.
For this study, 35 patients suffering from T2DM were included in Group 
“A,” who were taking insulin as their main treatment. Moreover, 35 
healthy participants were taken as controls, who were matched by age 
and gender, grouped as Group “B.” The study protocol was explained to 
the  patients, and their written consent was obtained. All patients were 
supplemented by ALA capsules (133 mg), 2 capsules/day for 6 months 
continuously.
•	 Inclusion	criteria	were	patients	with	T2DM	with	fasting	blood	sugar	




in	 spite	of	 antihypertensive	drugs);	patients	with	 complications	
of	diabetes	 including	nephropathy,	 retinopathy,	 and	neuropathy;	
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with	 known	 renal	 or	 hepatic	 diseases;	 and	 pregnant	 females,	
unwillingness to participate, or mental incapacity to take the drugs 
were excluded from the study.
A pro forma was designed to obtain basic demographic information 
taking data of weight and height. Their body mass index (BMI) was 
calculated using Quetelet’s index by formula weight/height2 and 
expressed in kg/m2. Blood samples collected for estimation of FBS, 
postprandial blood sugar (PPBS), glycosylated hemoglobin (HbA1c), 
lipid profile, and OS markers. FBS and PPBS were estimated by 
glucose oxidase method. HbA1c was calculated by cation exchange 
high-performance liquid chromatography using D-10-Hemoglobin 
Testing System (Bio-Rad). Lipid profiles were estimated using semi-
autoanalyzer, TRANSASIA, ERBA, and CHEM-5-PLUS. OS markers such 
as malondialdehyde (MDA), glutathione (GSH), and nitric oxide (NO) 
were measured using spectrophotometer.
Their baseline data and after 6 months supplementation data were 
compared among both groups. Statistical analysis was performed using 
Student’s paired t-test using SPSS software 20 version, and p<0.05 was 
considered statistically significant.
RESULTS
As shown in Table 1, there is non-significant difference in age, weight, 
and height of patients recruited in both groups, so they are matched 
by all these factors. We recruited 17 females and 18 males in Group A 
and 16 females and 19 males in Group B. Data are presented as mean ± 
standard deviation from mean.
Table 2 shows sugar levels such as FBS, PPBS, and HbA1c values at 
the initial stage of experiment. In the diabetic group, i.e., Group A has 
significantly more levels in comparison to Group B, where normal 
healthy controls were taken as control. As shown in Table 2, low-
density lipoprotein (LDL), very LDL (VLDL), triglyceride (TG), and 
total cholesterol (TCh) levels were more and high-density lipoprotein 
(HDL) is less in diabetic group, Group A than healthy group, Group B. OS 
markers such as plasma GSH and NO levels are less and high MDA level 
in Group A in comparison to Group B. 
Effects of administration of ALA on different parameters are shown 
in Table 3. It shows non-significant change of weight and BMI of both 
groups due to ALA effect. Sugar levels such as FBS and PPBS show a 
significant decrease after ALA supplement. HbA1c values show a 
significant decrease in Group A but non-significant decrease in Group B 
after ALA supplementation. Lipid profiles show a significant decrease 
in both groups due to ALA. OS shows significant decrease as shown by 
their markers in both groups due to ALA.
DISCUSSION
As shown in Table 1, all patients were matched by age and gender, also by 
their height, weight, and BMI. The basal values of sugar levels show higher 
values in Group A, who were diabetics. Due to worsening of hyperglycemia 
condition overtime, progressive decrease in beta-cell function occurs [16]. 
This demands added medications such as insulin and other oral 
hypoglycemic drugs to control this blood sugar level [17]. However, as 
there is multifactorial pathogenesis to develop different complications in 
T2DM, monotherapy appears insufficient to deal with T2DM [18,19].
ALA has antioxidant properties, can enhance glucose uptake in T2DM, 
and also can prevent ß-cell destruction in T1DM [20-24]. Results from 
this study indicate that oral ALA supplementation caused significant 
reduction in plasma FBS and PPBS levels in both groups. HbA1c level was 
significantly decreased in Group A, whereas a non-significant lowering 
of HbA1c level was seen in Group B. These data are in agreement with 
studies of Mazzone et al.,	1984	[25];	Packer	et al.,	2001	[26];	Maritim	
et al.,	 2003	 [27];	 and	 Kandeil	 et al., 2011 [28]. Glucose uptake is 
increased due to ALA as it increases glucose transporter translocation 
to cell membranes [29,30]. According to Sasvari and Nyakas, 2003 [31] 
and Bitar et al., 2004 [32], ALA activates the pathway of insulin 
signaling, causes phosphorylation of insulin receptors, and on myocytes 
and adipocytes, it exerts insulin-like actions [28,33].
Lipid profile levels show increased LDL, VLDL, TGs, and TCh levels 
in diabetic group, Group A in comparison to Group B. These results 
supported by other studies such as Monnier et al.,	1995	 [34];	Abdel-
Azim et al.,	2002	[35];	Mazzone	et al.,	1984	[25];	Sheela	and	Augusti,	
1992	 [36];	 and	 Sobenin	 et al., 1994 [37] studies. The abnormally 
high concentration of serum lipid profiles in T2DM is mainly a result 
of increased mobilization of free fatty acids from peripheral depots 
as insulin inhibits hormone-sensitive lipase, while glucagon and 
catecholamine enhance lipolysis [38,39].
Table 3 shows a significant lowering of LDL, VLDL, TG, and TCh levels 
and significant increase in HDL, the good cholesterol level after ALA 
treatment.	These	findings	are	in	accordance	with	Kocak	et al.,	2000	[40];	
Song et al.,	2005	[41];	and	Lee	et al., 2005 [42]. Researchers reveal that 
ALA activates catabolism of cholesterol into simpler components for 
the eventual synthesis of steroid hormones [43].
As shown in Table 2, OS markers such as GSH and NO levels, which 
combat the OS, are at lower level in Group A than Group B. Similarly, 
MDA a product of lipid peroxidation is significantly more in Group A 
than Group B. In patients with diabetes, there is increased production 
of AGEs [28] and due to overgeneration of reactive oxygen species 
(ROS), causing an imbalance and produces OS [44]. GSH is a tripeptide 
present in all cells in micromolar concentrations has great antioxidative 
property [45,46]. Low levels of GSH in T2DM patients in our study are in 
accordance withfindings of other studies [47-51].
ß-oxidation of fatty acids initiated by increased activity of enzyme 
fatty acyl coenzyme A oxidase due to hypoinsulinemia results 
lipid peroxidation [52]. The products of lipid peroxidation such as 
MDA are harmful to most of body cells and are associated different 
disease conditions such as brain damage, micro- and macrovascular 
complications [53].
ALA has amphiphilic nature and reduces ROS in cell membrane as 
well as at their mitochondrial source level [53-56]. Inside cells and 
tissues, ALA is reduced to dihydrolipoic acid that is even more potent 
antioxidant.
Table 1: Demographic data of both groups
Parameters Group A (n=35) Group B (n=35)
Age (years) 51.08±13.085 48.60±12.23 
Weight (kg) 60.914±9.546 62.400±6.869
Height (cm) 158.685±6.430 159.514±6.045
BMI (kg/m²) 24.046±2.263 24.505±2.111 
Table 2: Baseline sugar levels, lipid profile levels of both groups
Parameters Group A (n=35) Group B (n=35)
FBS (mg/dl) 161.31±15.94* 98.05±12.59*
PPBS (mg/dl) 211.37±22.30* 130.02±12.87*
HbA1c (%) 8.81±1.07* 5.26±0.42*
TCh (mg/dl) 223.34±25.77* 147.22±14.*83
TG (mg/dl) 175.57±29.83* 128.22±20.48*
HDL (mg/dl) 36.60±4.50* 39.34±3.21*
LDL (mg/dl) 161.85±19.60* 107.17±10.9*9
VLDL (mg/dl) 36.88±6.77* 28.80±4.22*
MDA (nm/ml) 1.967±0.581* 0.613±0.368*
GSH (µmol/L) 2.117±0.749* 2.631±0.495*
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Our results show after ALA supplementation OS levels were reduced, 
which support other studies [57-60].
CONCLUSION
Results obtained in our study indicate that the ALA can be used as an 
antioxidant in T2DM treatment along with the antidiabetic therapy 
to reduce different consequences as a result DM itself. ALA may be 
used to manage OS and dyslipidemic conditions developed due to 
hyperglycemic conditions in DM.
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